



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2013

PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Nine Months ended		Previous year ended
		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	11,942.71	15,141.23	6,239.48	37,950.90	18,318.10	25,788.46
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net) (a)+(b)	11,942.71	15,141.23	6,239.48	37,950.90	18,318.10	25,788.46
2	Expenses						
	a) Cost of materials consumed	3,576.20	4,200.48	2,364.64	11,151.23	6,192.93	8,827.40
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,024.28)	(727.64)	(773.81)	(1,737.23)	(744.88)	(559.63)
	d) Employee benefits expense	893.97	759.79	768.53	2,433.59	1,983.08	2,537.70
	e) Depreciation and amortisation expense	224.83	221.92	219.01	656.23	572.29	786.72
	f) Other expenses - Manufacturing Expenses	1,340.82	1,288.32	1,014.79	3,788.65	2,757.05	3,904.81
	- R & D Expenses	973.08	1,789.79	929.72	3,556.74	2,487.20	3,469.32
	- Others	694.40	689.27	448.96	1,824.99	1,683.38	2,290.30
	Total expenses	6,679.02	8,221.93	4,971.84	21,674.20	14,931.05	21,256.62
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	5,263.69	6,919.30	1,267.64	16,276.70	3,387.05	4,531.84
4	Other Income	84.96	11.41	36.84	411.90	50.05	104.34
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	5,348.65	6,930.71	1,304.48	16,688.60	3,437.10	4,636.18
6	Finance costs	221.43	341.28	468.53	881.77	1,080.20	1,350.94
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	5,127.22	6,589.43	835.95	15,806.83	2,356.90	3,285.24
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 + 8)	5,127.22	6,589.43	835.95	15,806.83	2,356.90	3,285.24
10	Tax Expenses	1,483.90	2,034.75	60.27	4,631.64	135.99	201.29
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	3,643.32	4,554.68	775.68	11,175.19	2,220.91	3,083.95
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	3,643.32	4,554.68	775.68	11,175.19	2,220.91	3,083.95
14	Share of profit / (loss) of associates	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	3,643.32	4,554.68	775.68	11,175.19	2,220.91	3,083.95
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,168.29	1,168.29	1,167.32	1,168.29	1,167.32	1,168.29
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	14,277.70
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	3.12	3.90	0.66	9.57	1.90	2.64
	b) Diluted	3.12	3.90	0.66	9.57	1.90	2.64
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):						
	a) Basic	3.12	3.90	0.66	9.57	1.90	2.64
	b) Diluted	3.12	3.90	0.66	9.57	1.90	2.64

PART - II		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
A	PARTICULARS OF SHAREHOLDING	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Public share holdings						
	a. Number of shares	41,171,212	41,171,212	42,679,160	41,171,212	42,679,160	41,993,960
	b. Percentage of share holding	35.24%	35.24%	36.56%	35.24%	36.56%	35.94%
2	Promoters and promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered						
	- Number of shares	75,657,576	75,657,576	74,052,828	75,657,576	74,052,828	74,834,828
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.76%	64.76%	63.44%	64.76%	63.44%	64.06%
	Particulars	3 months ended (31/12/2013)					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter	0					
	Received during the quarter	25					
	Disposed of during the quarter	25					
	Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							Rs. in lakhs
	PARTICULARS	Quarter ended			Nine Months ended		Year ended
		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012	31/03/2013
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	SEGMENT REVENUE						
	a) Manufacturing (CRAMS)	11,229.62	14,742.29	5,402.01	36,660.43	16,276.13	24,456.23
	b) Services (DDDSS)	713.08	398.95	837.46	1,290.46	2,041.96	1,332.24
	c) Research & Development	-	-	-	-	-	-
	Net sales/income from operations	11,942.70	15,141.24	6,239.47	37,950.89	18,318.09	25,788.47
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
	a) Manufacturing (CRAMS)	6,327.79	8,859.93	1,904.71	20,367.42	5,816.12	9,176.71
	b) Services (DDDSS)	459.14	213.02	618.02	687.99	1,255.51	370.00
	c) Research & Development	(973.08)	(1,789.79)	(929.72)	(3,556.74)	(2,487.20)	(3,469.32)
	TOTAL	5,813.85	7,283.16	1,593.01	17,498.67	4,584.43	6,077.39
	Less: (i) Interest	117.92	194.13	441.82	529.48	1,001.37	1,174.34
	(ii) Other Un-allocable expenses net off	568.71	499.60	315.24	1,162.36	1,226.56	1,617.81
	(iii) un-allocable Income	-	-	-	-	-	-
	Profit Before Tax	5,127.22	6,589.43	835.95	15,806.83	2,356.50	3,285.24
3	CAPITAL EMPLOYED (Segment Assets - Segment Liabilities)						
	a) Manufacturing (CRAMS)	21,824.86	23,091.94	13,053.17	21,824.86	13,053.17	13,212.39
	b) Services (DDDSS)	3,367.54	3,264.03	3,035.70	3,367.54	3,035.70	3,093.23
	c) Research & Development	2,136.36	2,259.21	2,157.59	2,136.36	2,157.59	2,503.65
	d) Net assets which are not segmented and used commonly	(707.60)	(5,637.34)	4,237.93	(707.60)	4,237.93	(3,363.29)
	TOTAL	26,621.16	22,977.84	22,484.39	26,621.16	22,484.39	15,445.98

Notes:

- The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 4th February, 2014.
- Previous years figures have been regrouped/reclassified whenever necessary.
- Suven Nishta Pharma Pvt Ltd., the 100% subsidiary, has been merged w.e.f. 1st January, 2012 and accordingly the results have been prepared. Hence the current quarter figures are not comparable with the previous corresponding quarter figures.
- The limited review for 3rd quarter has been done by the Statutory Auditors.

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI
Chairman & CEO

Place : Hyderabad

Date : 04th February, 2014

We Deliver



Ref No.LR/007/2013-14:

LIMITED REVIEW REPORT

To

The Bombay Stock Exchange Limited
Mumbai.

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad – 34, for the period ended on 31.12.2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India*. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)

(K. AJAY KUMAR)
P A R T N E R
M.No.021989



Place: Hyderabad
Date : 04/02/2014

News Release

Suven Q3 PAT up by 370% to Rs.36.43 Cr

HYDERABAD, INDIA (4 Feb' 2014) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services (CRAMS) company today announced its un-audited financial results for the quarter ended 31st Dec 2013. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 4th Feb 2014 at Hyderabad.

Financial Highlights for the 3rd Quarter ended Dec' 2013:

Growth in revenue	Rs 1203 Mn vs.Rs 628 Mn	- Up by 92%
Growth in PAT	Rs 364 Mn vs. Rs 78 Mn	- Up by 370%
Growth in EBIDTA	Rs 557 Mn vs. Rs 152 Mn	- Up by 266%

Financial Highlights for the 9 months period ended Dec' 2013:

Growth in revenue	Rs 3836 Mn vs.Rs 1837 Mn	- Up by 109%
Growth in PAT	Rs 1118 Mn vs. Rs 222 Mn	- Up by 403%
Growth in EBIDTA	Rs 1734 Mn vs. Rs 401 Mn	- Up by 333%

The growth in profit was a result of prelaunch supplies of 3 products under CRAMS.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 356 Mn (9.27% on revenue) for the Nine months period ended Dec ' 2013 for the accounting year 2013-14.

SUVN-502 undergoing phase 1b clinical trial in USA.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

SUVEN LIFE SCIENCES LIMITED

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: info@suven.com, www.suven.com